Doctors of BC Town Hall: Prescribing Therapies for Mild-Moderate COVID-19

February 9, 2022

Presenters: Jolanta Piszczek, Jennifer Grant, Eric Partlow, Maureen O’Donnell
We gratefully acknowledge that we are gathered on the unceded, traditional, and ancestral lands of First Nations in this place currently known as British Columbia where we work, play and live.

First Nations have been responsible for stewarding this land for all time and we give thanks as uninvited guests on these lands.
Goals for this webinar:

1. What new treatment options are available, evidence, and challenges (i.e., contraindications and interactions, side effects)?
2. Who are the patients who will most benefit?
3. What might a step-by-step assessment look like?
4. What’s our approach to implementation in BC?
5. Next steps for you
What is nirmatrelvir/ritonavir (Paxlovid)?

- Protease Inhibitor (PI) specific to SARS-COV-2
- Active against all variants of concern, including Omicron
- No measurable activity against human proteases; genotoxicity and mutagenicity not observed; similar side-effects to other PIs
- Extensively metabolized by CYP 3A4
  - T1/2 = 2hrs alone; extended by ritonavir
  - Nirmatrelvir is renally excreted
- 150mg/100mg nirmatrelvir/ritonavir tabs
  - 2 tabs/1 tab (300mg/100mg) PO BID
  - Kit contains 30 tabs
  - Renally adjusted for eGFR 30-60m/min
    - 150mg/100mg PO BID

**Graph to Illustrate PK Enhancer Concept**
Studying this medication: EPIC-HR Study

• Not published as of today; Health Canada issued a full Notice of Compliance
• Randomized, double-blind placebo-controlled trial
  • Conducted globally (41% participants from the US); 95% Delta VoC
  • Unvaccinated adults with mild-moderate COVID-19 at high-risk of progression
    • Age ≥ 60 or an at-risk condition (obesity, current smoker, heart disease, diabetes)
    • Randomized within 3 days of symptom onset, increased to 5 days after ~1/3 of ppt enrolled
• Primary end-point: 89% RRR; 5.8% ARR and NNT 17

<table>
<thead>
<tr>
<th>Efficacy outcome results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with COVID-19-related hospitalisation or death from any cause through Day 28</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Primary endpoint</td>
</tr>
<tr>
<td>Treatment within 3 days of symptom onset, n (%)</td>
</tr>
<tr>
<td>Secondary endpoint</td>
</tr>
<tr>
<td>Treatment within 5 days of symptom onset, n (%)</td>
</tr>
</tbody>
</table>

Source: Pfizer
Considerations/challenges with nirmatrelvir/ritonavir

- No peer-reviewed publication to critically appraise as of Feb 9, 2022
  - Who was excluded from the trial?
  - Treatment discontinuations
  - All-cause hospitalizations and all-cause mortality

- Recommendations are conditional and subject to change

- Trial conducted during Delta wave; generalizability to Omicron/BC

- Various contraindications – more real-world evidence is needed

- Very challenging drug-drug interactions
  - Many common drug classes, e.g., antiarrhythmics, anticoagulants, antiplatelet agents, statins, antipsychotics, opioids like fentanyl and methadone
  - Some can be managed but require additional steps
    - Check multiple resources, modify current therapy, consult, follow-up
What is sotrovimab (Xevudy)?

- Monoclonal antibody against spike protein
  - Large binding domain; maintained activity against Omicron
- Dosed 500mg IV x 1 dose IV infusion over an hour plus observation
- Evaluated in a randomized, double-blind placebo-controlled trial (COMET-ICE); similar to EPIC-HR (except all-cause primary endpoint)

### Table 2. Efficacy Outcomes through Day 29 (Intention-to-Treat Population).\(^*\)

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Sotrovimab (N = 291)</th>
<th>Placebo (N = 292)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary outcome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospitalization for &gt;24 hr for any cause or death from any cause — no. (%)</td>
<td>3 (1)</td>
<td>21 (7)</td>
</tr>
<tr>
<td>Hospitalization for &gt;24 hr for any cause</td>
<td>3 (1)</td>
<td>21 (7)</td>
</tr>
<tr>
<td>Death from any cause</td>
<td>0</td>
<td>1 (&lt;1)(^†)</td>
</tr>
</tbody>
</table>

Considerations/challenges with sotrovimab?

- Well-tolerated with few contraindications and no DDI
- Infusion time and operational challenges (e.g., location, IPC issues, staffing)
- High-cost therapy comparatively
- Unclear evidence for those who are immuno-competent or vaccinated as patients have or produce their own antibodies; data in seropositive patients is mixed
- Potential for resistance could emerge as seen with other mAbs
Goals for this webinar:

1. What new treatment options are available, evidence, and challenges (i.e., contraindications and interactions, side effects)?
2. Who are the patients who will most benefit?
3. What might a step-by-step assessment look like?
4. What’s our approach to implementation in BC?
5. Next steps for you
BC’s COVID-19 Clinical Therapeutics Committee (CTC) Recommendations

- Published on BCCDC Website
- **Conditional Recommendation** for nirmatrelvir/ritonavir (Paxlovid) – awaiting peer review evidence
- Search: BCCDC COVID-19 Therapeutics

**Clinical Practice Guide: Recommendations and Evidence** -
*new February 1, 2022*

<table>
<thead>
<tr>
<th>Therapy Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nirmatrelvir/ritonavir 300/100mg PO BID x 5 days is recommended within 5 days of symptom onset (CONDITIONAL RECOMMENDATION pending peer-reviewed publication)</td>
</tr>
<tr>
<td>Nirmatrelvir/ritonavir roll-out is gradual. Check with leadership if it can be used in your treatment setting (e.g., in-hospital, LTC)</td>
</tr>
<tr>
<td>OR, if drug-drug interactions or contraindications prohibit administration (See Practice Tool 3 – Drug Interactions and Contraindications)</td>
</tr>
<tr>
<td>Sotrovimab 500mg IV x 1 dose is recommended within 7 days of symptom onset as an alternative to nirmatrelvir, in cases where IV administration is feasible</td>
</tr>
</tbody>
</table>
Evidence for Multivariable Inclusion Criteria

Case hospitalization rate (%) by CEV, age, and vaccination status, BC, Dec

**BC-specific modeling; Omicron wave. BCCDC/HSAIR**
Focus: those with the most likelihood of benefit

Highest-risk individuals (~15% progression to severe illness)

---

**Who is the treatment currently being considered for?**

Refer to: [Practice Tool #1 - Assessment Steps](#) and [Practice Tool #2 - CEV Definitions](#)

*Patients who test positive for COVID-19* via a Polymerase Chain Reaction (PCR) or Rapid Antigen Test (RAT) test

*AND*

*Have been identified as being at increased risk* for needing to go to the hospital for COVID-19:
  - Immuno-compromised individuals identified as Clinically Extremely Vulnerable (CEV) Group 1 and Group 2 (CEV 1 and CEV 2), regardless of vaccine status or previous infection
    - *Not all children ages 12-17 who are CEV 1 or 2 will benefit from treatment. Those with multiple co-morbidities would have the highest benefit*
  - Unvaccinated or partially vaccinated individuals with high-risk conditions identified as CEV 3
  - Unvaccinated or partially vaccinated individuals:
    - aged ≥70 years with one or more chronic condition/co-morbidity
    - aged ≥ 60 years with three or more chronic conditions/co-morbidities
    - aged ≥ 60 years who are Indigenous

*Unvaccinated or partially vaccinated refers to the receipt of 0, 1 or 2 vaccine doses. Two doses of vaccine is considered partially vaccinated for these treatments.*
Considerations/challenges

- Assessing risk
- Symptom severity
- Symptom trajectory
- Symptom window
Goals for this webinar:

1. What new treatment options are available, evidence, and challenges (i.e., contraindications and interactions, side effects)?
2. Who are the patients who will most benefit?
3. What might a step-by-step assessment look like?
4. What’s our approach to implementation in BC?
5. Next steps for you
Step-by-step Clinical Assessment

• Omicron is highly variable in its clinical presentation

• Detailed assessment of risk factors:
  ▪ Age-associated risk
  ▪ Immunocompromise – CEV 1 and 2
  ▪ Vaccine status
  ▪ Comorbidities – type and number
  ▪ Clinical Status – symptoms, severity, trajectory

Practice Tool #1: Step-by-Step Assessment for Clinicians - new February 1, 2022

• This guide is a step-by-step clinical assessment tool for clinicians such as nurses or physicians who are directly involved in assessment and management of patients with mild-moderate COVID-19.
Assess Immunity: CEV 1 and 2

- Unable to mount a response to vaccine – humoral immunity
- Weak underlying immunity – innate immunity
  - A. Transplant
  - B. Active Chemotherapy
  - C. Severe primary immune deficiency syndromes
  - D. Potent immune suppression – anti-CD-20; B cell depleting
  - E. Other MAB’s
  - F. High dose steroids
  - G. MMF, cyclophosphamide, MTX

*Practice Tool #2: Definitions of Clinically Extremely Vulnerable (CEV) - new February 1, 2022*
Assess Vaccine Status

• Number of doses
  o For CEV1 and 2: can be offered treatment regardless of vaccine status
  o For the other high-risk populations: “inadequate” vaccination is less than 3 doses

• Type
  o mRNA, viral vector, out-of-country vaccines

• Timing
  o How long since the last dose?
  o Immunosuppression while vaccinated?

• Previous infection
  o May not confer protection against re-infection but the risk of hospitalization is low
Assess Co-morbidities

- Dramatic impact on risk
- Pulmonary disease
- DM on Insulin
- Dialysis and stage 5 CKD
- Mild-mod immunocompromise
- Many others – CHF, stroke, obesity, neuromuscular, smoking, frailty
- Use thermal chart in decision making with patients (in Practice Guide)
Assess Clinical Syndrome (symptoms)

Mild to Moderate Disease – symptomatic but not needing O₂ therapy

Severity types simplified:

1. "Cold" – sore throat, HA, congestion
   • Very mild 2-3 day illness for most vaccinated patients

2. "Flu" – severe HA, fever, myalgias, N/V, diarrhea
   • May be nearly bedridden

3. "Pneumonia/LRTI" – dyspnea, SOBOE, cough
   • May still not need O₂

Do not treat asymptomatic patients

Also consider symptom trajectory and symptom window

• Those who are visibly improving on their own
• Role for observation if early, mild, or improving
• Time for drug transport can be added to the symptom window for patients from rural/remote communities
Patient examples – both meet criteria

- 74 y/o – SOD 4
- 2 mRNA vaccines
- DM, HTN, CHF, COPD
- HA, fever, myalgia, cough
- Not improving/worsening
  ➢ High Risk
  ➢ Offer Treatment

- 48 y/o Ulcerative Colitis – SOD 4
- 2 mRNA vaccines
- Infliximab and MTX
- Mild illness – congestion, sore throat
- Day 4 of symptoms – resolving
  ➢ Meets criteria but Low risk
  ➢ Offer Reassurance, monitor
Resources: Clinical Practice Guide and Tools on BCCDC website

**Clinical Practice Guide: Recommendations and Evidence** - new February 1, 2022

**Practice Tool #1: Step-by-Step Assessment for Clinicians** - new February 1, 2022

**Practice Tool #2: Definitions of Clinically Extremely Vulnerable (CEV)** - new February 1, 2022

**Practice Tool #3: Drug-Drug Interactions and Contraindications** - updated February 3, 2022
Goals for this webinar:

1. What new treatment options are available, evidence, and challenges (i.e., contraindications and interactions, side effects)?
2. Who are the patients who will most benefit?
3. What might a step-by-step assessment look like?
4. What’s our approach to implementation in BC?
5. Next steps for you
Principles for implementation across BC

Provincial approach with equity
- All geographic regions have a plan and strive for equity in partnership with First Nations Health Authority.

Reach most-at-risk patients
- Strive for patients most at risk of the outcomes to receive the doses.

Safety in prescribing
- Thorough review of patients’ medications and medical histories needed, especially given that we, like the rest of the world, are learning about this new medication.

Evidence-informed
- Watching for more international evidence and gathering our own evidence/evaluation
Foundational supports

• Medication supply
• Medication distribution plan
• CTC guidance and clinical decision tools – posted on BCCDC
• A common special prescription form (not special authorization) which will also assist with monitoring and evaluation
• Opportunities to learn/webinars/academic detailing for physicians and pharmacists
• Mechanisms to serve unattached patients
• Increasing outpatient capacity for infusions in each health authority (for sotrovimab)
• Evaluation/ ongoing evidence review (especially via the CTC)
Why undertake a staged implementation?

• Reach patients with the highest risk/likelihood of benefit
• Providers (physicians and pharmacist): Given an opportunity to learn about these new therapeutics
• Development of physician and pharmacy expertise/”super-user” to support all providers
• Quickly widening supports for all physicians/NP’s to prescribe safely (including pharmacy consultation services, development of
• In the background:
  • Recognition that we are awaiting final peer-reviewed papers
  • Awaiting additional supply to the provinces
Staged approach to implementation

Wave 1: (started the week of January 31)
Infectious disease led teams in each HA – proactive outreach to PCR positive patients
BC Renal, BC Cancer, BC Transplant, and Cystic Fibrosis Care BC enabled and linked.
FNHA connected to receive support from health authorities as required.

Wave 2: (Goal: week of February 14th)
Long Term Care
Emergency Departments

Wave 3: (Goal: week of February 21 or earlier)
COVID Antiviral Therapeutics e-team (CATe) (Services BC, 8-1-1)

Wave 4: (Goal TBD - ? End of February/Early March)
Community family physicians and nurse practitioners
Goals for this webinar:

1. What new treatment options are available, evidence, and challenges (i.e., contraindications and interactions, side effects)?
2. Who are the patients who will most benefit?
3. What might a step-by-step assessment look like?
4. What’s our approach to implementation in BC?
5. Next steps for you
What does this mean for us as providers at this time? What are our next steps?

• Increased and ongoing need for evidence
  • Available resources (as per previous slides) (BCCDC website – CTC tools)
  • Will continue to also push news of new evidence

• For your high-risk patients – planning discussions and review
  • For PCR positive patients
    • Wave 1 – proactive outreach
    • Will shift in the weeks to come
  • For RAT positive patients
    • As patients reach out to you... Screening and assessing
    • HA contacts – ID led teams

• Additional supports to watch for: Pharmacy consultation support, CATe service providers as resources, DDI tools... and more...

• Feel prepared to prescribe: Online resources, take advantage of PAD if your group wishes

• Watch communication channels: Commitment to communicate as we move through the subsequent implementation waves quite quickly: DOBC, College, HA communications
Further education

Education sessions for Clinicians

For more information on nirmatrelvir/ritonavir:

• BC PAD service is providing additional education sessions via ZOOM focussing on eligibility criteria and drug-drug interaction management
• To schedule: email PAD@gov.bc.ca
• Provide:
  • contact name, email, phone number
  • 3 possible dates & times
  • Approximate group size (max. 100)
  • Your group’s specialty area
Goals for this webinar:

1. What new treatment options are available, evidence, and challenges (i.e., contraindications and interactions, side effects)?
2. Who are the patients who will most benefit?
3. What might a step-by-step assessment look like?
4. What’s our approach to implementation in BC?
5. Next steps for you

6. Questions!? 